Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
CHINA-BIOTICS, INC (CHBT)
|
Add to portfolio |
|
|
|
| Price: |
$0.50
| | Metrics |
| OS: |
22.2
|
M
| |
|
|
| Market cap: |
$11.1
|
M
| |
|
|
|
Net cash:
|
$86.1
|
M
| |
$3.89
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$31.0
|
M
| |
-2.4
|
x EV/EBITDA
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Mar-31-13 | Mar-31-12 | Mar-31-11 | Mar-31-10 | Mar-31-09 | Mar-31-08 | Mar-31-07 | Mar-31-06 |
| Revenues | 3.1 | 0.8 | 108.8 | 81.4 | 54.2 | 42.8 | 30.6 | 21.9 |
| Revenue growth | 277.2% | -99.3% | 33.7% | 50.1% | 26.8% | 39.7% | 39.5% | |
| Cost of goods sold | 31.5 | 26.2 | 38.9 | 24.1 | 16.2 | -12.3 | -8.9 | -6.4 |
| Gross profit | -28.5 | -25.4 | 69.9 | 57.3 | 38.0 | 55.1 | 39.5 | 28.4 |
| Gross margin | -933.4% | -3135.1% | 64.2% | 70.4% | 70.1% | 128.8% | 129.1% | 129.4% |
| Sales and marketing | 11.6 | 5.6 | 13.9 | 13.5 | 11.6 | 6.9 | 4.5 | 2.4 |
| Research and development | | | | | | 2.2 | | |
| General and administrative | 12.0 | 11.2 | 13.5 | 4.9 | 3.0 | 2.6 | 2.3 | 0.8 |
| EBITA | 16.4 | 3.6 | 35.8 | 35.3 | 21.8 | 22.1 | 14.9 | 12.2 |
| EBITA margin | 538.2% | 451.0% | 32.9% | 43.4% | 40.3% | 51.7% | 48.8% | 55.6% |
| Amortization of intangibles | 0.1 | 0.0 | 0.1 | 0.0 | 0.0 | | | |
| EBIT | 16.3 | 3.6 | 35.7 | 35.3 | 21.8 | 22.1 | 14.9 | 12.2 |
| EBIT margin | 534.8% | 444.9% | 32.8% | 43.4% | 40.2% | 51.7% | 48.8% | 55.6% |
| Pre-tax income | 19.2 | 5.6 | 45.9 | 23.4 | 25.1 | 22.5 | 15.1 | 12.3 |
| Income taxes | 3.8 | 2.8 | 9.0 | 7.8 | 5.2 | 4.9 | 4.2 | 3.9 |
| Tax rate | 19.9% | 50.5% | 19.6% | 33.2% | 20.5% | 22.0% | 27.7% | 31.8% |
| Net income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 17.5 | 10.9 | 8.4 |
| Net margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 41.0% | 35.6% | 38.1% |
| |
| Diluted EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.03 | $0.64 | $4.90 |
| Shares outstanding (diluted) | 22.2 | 22.3 | 23.7 | 19.6 | 17.1 | 17.1 | 17.1 | 1.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|